A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
Dementia, Alzheimer Disease
About this trial
This is an interventional treatment trial for Dementia focused on measuring Mild cognitive impairment, Galantamine hydrobromide, Memory disorders
Eligibility Criteria
Inclusion Criteria: Clinical decline of cognitive ability consistent with mild cognitive impairment Delayed recall score <= 10 on a New York University paragraph recall test Sufficient visual, hearing and communication capabilities and be willing to complete serial standard tests of cognitive function Have a consistent informant to accompany them on scheduled visits Be able to read, write and fully understand the language of the cognitive scales used in the study Exclusion Criteria: Neurodegenerative disorders such as Parkinson's disease Cognitive impairment resulting from acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency states, infections such as meningitis or AIDS, or primary or metastatic cerebral neoplasia Epilepsy Significant psychiatric disease Peptic ulcer disease Clinically significant heart, lung, liver or kidney diseases Pregnant or nursing women or those without adequate contraception